| Date | Title | Description |
| 14.03.2024 | Cumulus Neuroscience Announces First Patient Enrolled in AccelADx Electroencephalogram (EEG) Study for Early Detection of Alzheimer's Dementia | NIHR-Funded Study Represents the Largest of its Kind Conducted to Date in Alzheimer's Dementia.
Cumulus Neuroscience today announced the enrollment of the first patient in a major research collaboration with the Universities of Bath and Bri... |
| 12.03.2024 | Prilenia Plans to Submit Marketing Authorization Application (MAA) in the EU for Pridopidine in Huntington’s Disease | -Following positive pre-submission meetings with regulators, Prilenia plans to submit its MAA for pridopidine in Huntington’s disease (HD) in mid-2024-
-If approved, pridopidine could be commercially available to patients in Europe as early... |
| 11.03.2024 | Ribometrix to Present New Preclinical Data From RNA-Modulating Small Molecule Programs Targeting eIF4E and c-MYC at the 2024 AACR Annual Meeting | — Data demonstrate in vivo tumor regression via RNA-binding protein inhibitor targeting eIF4E in multiple tumor types with significant unmet need —
— First data disclosure from the Company’s RNA-targeting small molecule platform and its pro... |
| 11.03.2024 | Nitrase Therapeutics Unveils Pioneering Antibody Candidate for Parkinson’s Disease Based on Nitration Discovery in Oral Presentation at the Alzheimer’s Disease and Parkinson’s Disease (AD/PD) Conferen... | -Nitrase’s first-in-class antibody found to significantly delay progression of Parkinson’s disease in preclinical models by blocking the propagation of pathogenic nitrated synuclein
-Advancing development candidate NDC-0524 into IND-enablin... |
| 08.03.2024 | On International Women's Day SV Venture Partner Ruth McKernan reflects on some achievements of SV biotech portfolio companies | On International Women’s Day it is extremely pleasing to note the vast majority of SV Health Investor’s biotech portfolio companies with women in their C-suite, many being led by female CEOs. It is one of the many reasons I was drawn to wor... |
| 04.03.2024 | QurAlis to Present Data That Show its Splice-Switching ASOs Restore UNC13A Function in ALS and Frontotemporal Dementia | UNC13A is an essential regulator of neurotransmitter release at synapses; mis-splicing is a critical RNA alteration occurring in up to 63 percent of all ALS patients and up to one-third of all FTD cases
Preclinical data to be featured in a ... |
| 13.02.2024 | EyeBio Announces Positive Visual, Anatomic and Safety Data from First-in-Human Ph1b/2a AMARONE Trial of Restoret at Macula Society Annual Meeting | Twelve week data from the Ph1b/2a AMARONE trial reveals Restoret to be well-tolerated in patients with diabetic macular edema and neovascular age-related macular degeneration. Proof of concept established with strong visual and anatomic out... |
| 13.02.2024 | EyeBio targets registrational trial after early success of Wnt agonist in retinal diseases | EyeBio’s tri-specific Wnt agonist antibody improved visual and anatomical measures in a Phase Ib/IIa trial as a monotherapy and in combination with Regeneron’s Eylea, prompting preliminary plans for a potential registrational study in retin... |
| 13.02.2024 | Transposon Announces Final Results from a Phase 2 Study of its LINE-1 Reverse Transcriptase Inhibitor TPN-101 for the Treatment of Progressive Supranuclear Palsy and Interim Results from a Phase 2 Stu... | SAN DIEGO, Feb. 12, 2024 /PRNewswire/ -- Transposon Therapeutics, a biotechnology company developing a platform of novel, orally administered therapies for the treatment of neurodegenerative and aging-related diseases including Alzheimer's ... |
| 13.02.2024 | Sudo Biosciences Announces Second Close of Upsized Series B Financing Bringing Total Raised in Round to $147M | CARMEL, IN - Sudo Biosciences (“Sudo”), a biopharmaceutical company committed to designing and developing best-in-class precision TYK2 (tyrosine kinase 2) inhibitors, today announced that during January 2024, it completed a second close of ... |
| 13.02.2024 | BioAge raises $170M as obesity spotlight shifts to oral options, muscle preservers | BioAge Labs has reeled in the biotech industry’s largest private financing round so far in 2024 as the California startup goes full throttle on the hottest areas in obesity drug development: oral formulations and muscle preservation. |
| 13.02.2024 | BioAge Announces $170 Million Oversubscribed Series D Financing to Accelerate Development of Obesity and Metabolic Disease Therapeutics | February 13, 2024 08:00 AM Eastern Standard Time
RICHMOND, Calif.--(BUSINESS WIRE)--BioAge Labs (“BioAge”), a clinical-stage biotechnology company developing novel therapies for obesity and metabolic diseases by harnessing the biology of ag... |
| 07.02.2024 | Kate Bingham Participates in The Times' Health Commission Report Summit | The government’s former chief scientific adviser [Sir Patrick Vallance] told The Times Health Commission that the NHS must learn from the Covid vaccine taskforce and take risks to improve |
| 24.01.2024 | Amphista Therapeutics announces new data demonstrating in vivo efficacy and CNS activity of its mechanistically differentiated targeted protein degraders | Cambridge, UK, January 24th, 2024 – Amphista Therapeutics (“the Company” or “Amphista”), a leader in next generation targeted protein degradation (TPD) approaches, today announces the achievement of two compelling new data sets with its nex... |
| 19.01.2024 | Prilenia Announces Clinical Data in Support of its Plans to Initiate Global Phase 3 Study in ALS | NAARDEN, Netherlands and WALTHAM, Mass., 19 January 2024 --- Prilenia Therapeutics B.V., a clinical stage biotechnology company focused on the urgent mission to develop novel therapeutics to slow the progression of neurodegenerative disease... |
| 11.01.2024 | SV investment has resulted in the approval of 24 novel therapeutics | SV approved therapeutics |
| 08.01.2024 | SV is hiring: Executive Assistant | Position Title: Executive Assistant – Venture Capital/Growth Equity Firm |
| 08.01.2024 | SV is hiring: Analyst / Associate - Biotech team | Position Title: Analyst / Associate - Biotech team |
| 04.01.2024 | Sitryx announces collaboration partner Lilly has commenced a Phase 1 study of SIT-011 for chronic autoimmune and inflammatory diseases | Oxford, UK – 4 January 2024 – Sitryx Therapeutics (“the Company”), a biopharmaceutical company focused on regulating cell metabolism to develop disease-modifying therapeutics for chronic autoimmune and inflammatory diseases, today announces... |
| 04.01.2024 | Boehringer Ingelheim licenses multiple Dark Antigens® from Enara Bio to develop off-the-shelf immunotherapies for non-small cell lung cancer (NSCLC) | Oxford, UK – January 04, 2024. Enara Bio today announces that Boehringer Ingelheim has exercised its option to license a number of cancer antigens discovered and validated through the ongoing collaboration using Enara Bio’s Dark Antigen dis... |
| 04.01.2024 | SV Health Investors bolsters senior biotech team - appoints Nikola Trbovic as Managing Partner and hires Jamil Beg as Partner | LONDON - BOSTON, 04 January 2024 (GLOBE NEWSWIRE) - SV Health Investors, a leading transatlantic venture capital and growth equity firm, is pleased to announce that it is bolstering its senior biotech team with the appointments of Nikola Tr... |
| 03.01.2024 | QurAlis Strengthens Global Presence With Opening of European Headquarters That Includes R&D Manufacturing | New location in Leiden, The Netherlands will serve as hub for European operations and production of QurAlis' products for clinical trials through commercialization |
| 20.12.2023 | Perfuze® Announces FDA Clearances for Novel Neurovascular Aspiration and Access Catheters for Stroke Treatment | Galway, Ireland, December 20, 2023 –Perfuze, a private medical device company dedicated to developing pioneering technology to treat acute ischemic stroke, proudly announces FDA clearance for the Millipede 070 Aspiration Catheter and the 2n... |
| 13.12.2023 | Hightop Health adds industry veteran to Board of Directors - Seasoned CEO and McLean Hospital Board Chair joins Hightop’s executive leadership | Atlanta, GA (December 13, 2023) –Hightop Health, a premier outpatient mental health platform, today announced the appointment of Carol Vallone as its Independent Board Director. |
| 28.11.2023 | Harness Therapeutics secures additional £4 million funding to pursue physiological upregulation approach to treat neurodegenerative diseases | Cambridge, UK, 28th November 2023: Harness Therapeutics (‘Harness’, previously Transine Therapeutics), a biotechnology company focused on physiological protein upregulation to develop next generation therapeutics for the treatment of neurod... |
| 21.11.2023 | Merck to Acquire Caraway Therapeutics, Inc. | Acquisition underscores Merck’s ongoing commitment to developing treatments for neurodegenerative diseases |
| 21.11.2023 | Dementia Discovery Fund Announces the Acquisition of Caraway Therapeutics by Merck | This transaction highlights DDF’s attractive strategy of investing in novel therapeutics for dementia, a rapidly escalating public health crisis. |
| 14.11.2023 | Transposon Announces Interim Results from a Phase 2 Study of TPN-101 for the Treatment of Progressive Supranuclear Palsy to be Presented at the AD/PD™ 2024 International Conference on Alzheimer's and ... | 24-Week data show TPN-101 is the first treatment for PSP to reduce NfL levels, a key biomarker of neurodegeneration in tauopathies such as PSP and Alzheimer's disease |
| 14.11.2023 | EyeBio Announces Expansion of Series A to $130 Million, Advances Development of Restoret for Retinal Diseases | EyeBio doubles the size of its original Series A raise with an additional $65 million, with new investors Bain Capital Life Sciences, Omega Funds and Vertex Ventures HC joining the round to support accelerated development of its innovative ... |
| 13.11.2023 | Cerevance Doses First Patient in ASCEND Phase 2 Clinical Study of CVN424, a First-in-Class, Non-Dopaminergic Therapy for the Treatment of Parkinson’s Disease | Boston, MA – November 13, 2023 – Cerevance, a company focused on developing novel precision therapeutics for central nervous system (CNS) diseases, today announced that the first subject has been dosed in the Phase 2 clinical study of CVN42... |
| 12.11.2023 | Imbria Reports Positive Topline Results for Investigational New Drug Ninerafaxstat in Patients with Cardiac Ischemia and Chronic Stable Angina | – The IMPROVE-ISCHEMIA Phase 2 clinical trial met the primary endpoint of tolerability and safety; 8-weeks treatment with ninerafaxstat also demonstrated a statistically significant improvement in dobutamine stress-induced ischemic left ven... |
| 08.11.2023 | SV Health Investors partners with HIT Executives Dave Dyell and Marc Hirshfield to Lead Recapitalization of Innovative Consulting Group | Panama City, Fla.—November 8, 2023—SV Health Investors (SVHI), a private healthcare investment firm with offices in Boston and London, is partnering with HIT executives Dave Dyell and Marc Hirshfield to recapitalize U.S.-based Innovative Co... |
| 07.11.2023 | Imbria Reports Positive Topline Results for Investigational New Drug Ninerafaxstat in Patients with Non-obstructive Hypertrophic Cardiomyopathy | – The IMPROVE-HCM Phase 2 clinical trial met the primary endpoint of safety and tolerability; 12-weeks treatment with ninerafaxstat also demonstrated a statistically significant improvement, compared to placebo, in a robust functional cardi... |
| 06.11.2023 | AviadoBio Announces FDA IND Clearance and Fast Track Designation for AVB-101 for the Treatment of Frontotemporal Dementia with Progranulin (GRN) Mutations | • AVB-101 is an investigational gene therapy delivered as a one-time infusion directly to the brain, enabling distribution to brain areas affected by FTD while limiting systemic exposure |
| 02.11.2023 | Perfuze Announces First Stroke Patient Enrolled in the MARRS Pivotal Clinical Trial for the Millipede System | Galway, Ireland, November 2, 2023 –Perfuze, a private medical device company dedicated to developing pioneering technology to treat acute ischemic stroke, announced commencement of enrollment in its pivotal MARRS (Millipede AspiRation for R... |
| 01.11.2023 | Sitryx announces partner Lilly exercises option to SIT-011 for chronic autoimmune and inflammatory diseases | Oxford, UK – 1 November 2023 – Sitryx Therapeutics (“the Company”), a biopharmaceutical company focused on regulating cell metabolism to develop disease-modifying therapeutics for chronic autoimmune and inflammatory diseases, today announce... |
| 01.11.2023 | Vibrato Medical Announces Positive Results for Early Feasibility Study of Wearable, Non-Invasive Therapeutic Ultrasound to Treat Chronic Limb-Threatening Ischemia | NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Vibrato Medical, an innovator in the treatment of peripheral arterial disease (PAD), announced today that data from an early feasibility study of Non-Invasive Therapeutic Ultrasound (TUS) to treat Chr... |
| 23.10.2023 | Hightop Health Launches Unique Outpatient Mental Health Platform | Boston, MA (October 23, 2023) – SV Health Investors (“SVHI”), a Boston-based healthcare private investment firm, announced today an investment in Hightop Health (“Hightop”), an outpatient mental health platform focused on an integrative, ev... |
| 18.10.2023 | Cumulus Neuroscience to Present Data at CTAD 2023 Annual Meeting | BELFAST, Northern Ireland and CAMBRIDGE, Mass., October 18, 2023 / -- Cumulus Neuroscience (Cumulus; The Company), a global digital health company focused on advancing neuroscience clinical trials and patient care through improved data, wil... |
| 16.10.2023 | Pulmocide Announces New Clinical Data Confirming Low Potential for Drug-Drug Interactions with Inhaled Opelconazole | LONDON, Oct. 16, 2023 (GLOBE NEWSWIRE) -- Pulmocide Ltd., (“the Company”) a late-stage biopharmaceutical company developing novel inhaled therapies for patients suffering from serious acute and chronic respiratory diseases, today announced ... |
| 12.10.2023 | Mestag Therapeutics announces the appointment of expert advisors Dr. Cassandra Choe-Juliak, Dr. Greg Elson and Samantha Vieira MBA | Cambridge, UK, October 12, 2023 – Mestag Therapeutics (“Mestag”), a biotech company harnessing new insights into fibroblast-immune interactions to develop impactful treatments for patients, today announced the appointment of expert advisors... |
| 10.10.2023 | AviadoBio Announces Initiation of Phase 1/2 Clinical Trial, ASPIRE-FTD, Evaluating AVB-101 in People with Frontotemporal Dementia with GRN Mutations | • AVB-101 is an investigational gene therapy designed to halt disease progression by delivering a functional copy of the GRN gene to restore appropriate progranulin levels in the brain |
| 09.10.2023 | AstronauTx closes a £48 million ($61 million) Series A financing to create new treatments for Alzheimer’s disease | London UK, XXXX– AstronauTx Ltd. (“AstronauTx”), a biotech company developing novel treatments for Alzheimer’s disease and other neurodegenerative disorders today announced the completion of a £48 million ($61 million) Series A financing.... |
| 08.10.2023 | UK biotech group raises £48mn for Alzheimer’s research | AstronauTx’s financing is step towards helping millions of people suffering from disease |
| 05.10.2023 | Sean M. Healey & AMG Center for ALS awarded NIH U01 Grant to support Expanded Access to Pridopidine in Collaboration with Prilenia Therapeutics | The Sean M. Healey & AMG Center for ALS at Massachusetts General Hospital has been awarded a grant from the National Institutes of Health (NIH) - Neurological Disorders and Stroke (NINDS) to conduct an intermediate size Expanded Access ... |
| 29.09.2023 | The Guardian: Pioneering a new era for dementia care | DDF Understanding Dementia |
| 27.09.2023 | Sitryx raises additional $39 million to progress development of disease-modifying therapeutics for chronic autoimmune and inflammatory diseases | Oxford, UK – 27 September 2023 – Sitryx Therapeutics (“the Company”), a biopharmaceutical company focused on regulating cell metabolism to develop disease-modifying therapeutics for chronic autoimmune and inflammatory diseases, today announ... |
| 06.09.2023 | Nimbus is back for more, raising $210M to fuel pipeline seven months after $4B Takeda deal | What kind of biotech company returns billions to its investors without ever opening a lab, commercializing a drug, or going public with an IPO? |
| 06.09.2023 | Nimbus Therapeutics Secures $210M Private Financing to Advance Next Wave of Tech-Enabled Small Molecule Medicines | – GV joins the company’s distinguished investor base, validating Nimbus’ computational drug discovery engine and early clinical capabilities – |
| 03.09.2023 | British biotech faces a funding battle in race with the US | Quell Therapeutics, an SV portfolio company which recently entered into an exclusive option and license agreement with AZ receiving $85m upfront and a potential further $2bn for development and commercialisation milestones has been intervie... |
| 28.08.2023 | Fierce Biotech Names Cerevance a “Fierce 15” Biotech Company of 2023 | Boston, MA – August 28, 2023 – Cerevance, a private, clinical-stage drug discovery and development company focused on advancing novel, precision neuroscience therapeutics for central nervous system (CNS) diseases using the company’s proprie... |
| 16.08.2023 | Imbria Pharmaceuticals Completes Enrollment in the Phase 2 IMPROVE-ISCHEMIA Clinical Trial of Ninerafaxstat in Patients with Stable Angina | – IMPROVE-ISCHEMIA, a randomized, placebo-controlled trial, with topline data expected in 4Q 2023 – |
| 07.08.2023 | Ikena Oncology Acquires Pionyr Immunotherapeutics in All-Stock Transaction | Ikena receives approximately $43 million in net cash at closing |
| 25.07.2023 | A born listener: CNS startup Violet hones in on cellular cross-talk | The identification of new targets in diseases of the central nervous system (CNS) such as Alzheimer’s and Parkinson’s – conditions which continue to have significant unmet needs – has taken a small step forward as one company, Violet Therap... |
| 17.07.2023 | AI-Enabled Senior Care Company CarePredict Scores $29M | The company will use the funds to speed up its growth. |
| 06.07.2023 | DDF: Unleashing innovation, a new era for dementia | Dementia, the looming health crisis of our time, has long lacked effective treatments. But now, recent drug breakthroughs and the pioneering Dementia Discovery Fund offer hope for a brighter future.
By Laurence Barker and Jonathan Behr, bot... |
| 28.06.2023 | Renowned Neuroscientist Prof. Michael Heneka, M.D, Joins The Dementia Discovery Fund (DDF) as Scientific Advisor | Boston, MA (US) and London (UK) –June 28th 2023. The Dementia Discovery Fund (DDF), the world’s largest family of specialized venture capital funds dedicated to investing in novel treatments for neurodegenerative disorders causing dementia,... |
| 27.06.2023 | Mestag Therapeutics and VIB enter into an exclusive partnership in oncology | Cambridge, UK, and Ghent, Belgium, June 27, 2023 – Mestag Therapeutics (‘Mestag’), an immunotherapy company focusing on fibroblast-immune interactions, and VIB, the leading life science research institute in Flanders, today announced enteri... |
| 26.06.2023 | SV Health Investors Completes Partnership with Packaging Compliance Labs | Boston, MA (June 26, 2023) – SV Health Investors (“SVHI”), a Boston-based private investment firm focused exclusively on the healthcare industry, announced today an investment in Packaging Compliance Labs (“PCL”). Headquartered in Grand Rap... |
| 20.06.2023 | SV Health Investors Acquires Robling Medical | Boston, MA(June 20, 2023) – SV Health Investors (“SVHI”), a Boston-based private investment firm focused exclusively on the healthcare industry, announced today the acquisition of a controlling interest in Robling Medical (“Robling”). Headq... |
| 14.06.2023 | EyeBio Announces First Patients Dosed in Phase 1b/2 Trial of Restoret™ in Neovascular Age Related Macular Degeneration and Diabetic Macular Edema | AMARONE (Anti-permeability Mechanism and Age-Related Ocular Neovascularization Evaluation) is first clinical trial of EyeBio’s lead asset Restoret, a Wnt agonist, in two retinal diseases of permeability |
| 13.06.2023 | Autifony Therapeutics announces commencement of a US Phase Ib study of AUT00201, a novel Kv3 modulator, in Progressive Myoclonic Epilepsy-7 (EPM7) | Stevenage, UK - 13 June 2023 - Autifony Therapeutics Limited (“Autifony”), which is pioneering the development of novel pharmaceutical treatments for rare CNS disorders and other serious brain diseases, today announced that a Phase Ib trial... |
| 09.06.2023 | Quell Therapeutics Signs a Collaboration, Exclusive Option and License Agreement with AstraZeneca to Develop, Manufacture and Commercialize Engineered Treg Cell Therapies for Autoimmune Diseases | London, UK – June 9 2023 – Quell Therapeutics Ltd (“Quell”), a leader in developing engineered T-regulatory (Treg) cell therapies for serious medical conditions driven by the immune system today announced that it has entered into a collabor... |
| 09.06.2023 | UK cell therapy start-up agrees AstraZeneca partnership worth up to $2bn | Quell Therapeutics is developing cell engineering that aims to treat autoimmune diseases |
| 08.06.2023 | Pulmocide Announces Expansion of Management Team | LONDON, June 08, 2023 (GLOBE NEWSWIRE) -- Pulmocide Ltd., (“the Company”) a late-stage biopharmaceutical company developing novel inhaled therapies for patients suffering from serious acute and chronic respiratory diseases, today announced ... |
| 05.06.2023 | Imbria Pharmaceuticals Completes Enrollment in Phase 2 IMPROVE-HCM Trial of Ninerafaxstat in Patients with Non-obstructive Hypertrophic Cardiomyopathy | – Enrollment exceeded expectations, thus highlighting the large unmet need in non-obstructive hypertrophic cardiomyopathy – |
| 31.05.2023 | Violet Therapeutics raises $10.6 million in seed funding led by the Dementia Discovery Fund (through DDF-2) and co-led by UTEC (University of Tokyo Edge Capital Partners) and Mass General Brigham Vent... | Round led by the DDF (through DDF-2) and co-led by UTEC (University of Tokyo Edge Capital Partners) and founding investor Mass General Brigham Ventures (MGBV), and joined by Ono Venture Investment |
| 31.05.2023 | Cumulus Neuroscience Completes Patient Enrollment for Pivotal CNS-101 Early-Stage Alzheimer's Dementia Validation Trial | Oxford and Cambridge Among Sites Participating in CNS-101 Validation Study |
| 19.05.2023 | First Steps to Treating Dementia May Lie in Related Diseases | AARP-backed research into ALS, Alzheimer’s could lead to dementia drugs |
| 15.05.2023 | Therini Bio Initiates First-In-Human Dosing in Phase 1 Trial of THN391, a Fibrin-Targeting Therapeutic Candidate for Alzheimer’s Disease | SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Therini Bio, Inc., a biotech company focused on developing fibrin-targeted therapies to treat inflammatory neurodegenerative and retinal diseases, today announced the initiation of first-in-huma... |
| 01.05.2023 | Astellas Pharma buys Iveric Bio for $5.9 billion | Japan's Astellas Pharma said on Monday it agreed to buy U.S. drugmaker Iveric Bio Inc for about $5.9 billion in its biggest acquisition, giving it access to a range of ophthalmology treatments. |
| 27.04.2023 | Therini Bio Raises $36M Series A Financing to Develop Fibrin-Targeted Therapies for Neurodegenerative and Retinal Diseases | Funding from top-tier syndicate will be used to advance potential first-in-class investigational antibody THN391 into clinical trials. |
| 18.04.2023 | Nitrase Therapeutics Presents Preclinical Data on the Role of Enzymatic Nitration in Oncology at the American Association for Cancer Research Annual Meeting | BRISBANE, Calif., April 18, 2023 (GLOBE NEWSWIRE) -- Nitrase Therapeutics, Inc., a biopharmaceutical company deploying its NITROME platform to build a pipeline of therapies targeting nitrases, a new class of enzymes discovered in-house that... |
| 06.04.2023 | QurAlis Announces First Patient Dosed With QRL-201, a First-in-Class STATHMIN-2 Precision Therapy for ALS | First patient dosed in Canada in Phase 1 ANQUR study – the first-ever clinical trial to evaluate a therapy that rescues STATHMIN-2 expression in ALS patients |
| 28.03.2023 | Prilenia Achieves Last Patient Last Visit in Phase 3 PROOF-HD Clinical Study for Huntington’s Disease | PROOF-HD is the only late-stage study in Huntington’s disease targeting clinical progression; topline results expected in early Q2 2023 |
| 28.03.2023 | Bicycle Therapeutics Announces a Strategic Collaboration with Novartis to Discover, Develop and Commercialize Bicycle® Radio-Conjugates | - Bicycle and Novartis will collaborate on the discovery and development of multiple targeted radioligand therapies in oncology |
| 09.03.2023 | ALS biotech QurAlis gets $88M boost from four pharmas for pair of PhI studies | QurAlis picked up $88 million for two Phase I studies, hoping to ride regulatory waves driven by the recent FDA approval of Amylyx Pharmaceuticals’ ALS therapy. |
| 09.03.2023 | QurAlis Closes $88 Million Series B Financing to Advance Precision Medicines for Neurodegenerative Diseases | EQT Life Sciences, Droia Ventures, and Sanofi Ventures led the round |
| 06.03.2023 | EyeBio Announces First Asset in Innovative Pipeline of Retinal Disease Treatments and Appoints Industry Leaders to Executive Team | Additions to EyeBio’s leadership team include world-class disrupters with deep experience addressing urgent unmet needs in treatment of eye diseases |
| 23.02.2023 | AviadoBio Signs Exclusive License Agreement with Neurgain Technologies for Novel Gene Therapy Spinal Delivery Technology | • Subpial delivery technology has the potential to offer precise, efficient, and safer delivery of gene therapies for neurological diseases with spinal cord involvement |
| 23.02.2023 | Prilenia Announces Topline Results for Pridopidine in Phase 2 ALS Study | Naarden, NL and WALTHAM, Mass, 23 February 2023 – Prilenia Therapeutics B.V., a clinical stage biotechnology company focused on the urgent mission to develop novel therapeutics to slow the progression of neurodegenerative and neurodevelopme... |
| 20.02.2023 | Impact funds help fight dementia and antibiotic resistance | Some of the world’s biggest health challenges do not lend themselves to conventional investment |
| 16.02.2023 | Perfuze Announces FDA Clearance and First U.S. Clinical Use of Millipede 088 Access Catheter | GALWAY, Ireland--(BUSINESS WIRE)--Perfuze, a medical device company developing next-generation catheter-based technology to treat acute ischemic stroke, has secured its first product clearance from the U.S. Food and Drug Administration (FDA... |
| 13.02.2023 | Cerevance Expands Series B Financing with Additional $51 Million | Proceeds will advance Cerevance’s potential first-in-class programs developed using proprietary NETSseq platform |
| 08.02.2023 | Nimbus Therapeutics Announces Closing of Takeda's Acquisition of TYK2 Subsidiary | BOSTON, Mass. – February 8, 2023 – Nimbus Therapeutics, LLC (“Nimbus Therapeutics” or “Nimbus”), a clinical-stage company that designs and develops breakthrough medicines through its powerful computational drug discovery engine, today annou... |
| 25.01.2023 | HPS/PayMedix Closes on $25 Million in New Funding | Credit funds managed by SVB Capital lead new funding round to finance growth of PayMedix Healthcare Payment Solution |
| 24.01.2023 | Britain is losing its chance to become a life sciences superpower | Short-termism and suspicion in parts of government risk our valuable future in precision medicine |
| 16.01.2023 | British Patient Capital and Mubadala Invest in SV Biotech Crossover Opportunities Fund | 16 January 2023: British Patient Capital and Mubadala Investment Company (Mubadala), an Abu Dhabi-based sovereign investor, today announced their investment into the SV Biotech Crossover Opportunities Fund (SV BCOF). The co-investment betwe... |
| 12.01.2023 | Feinstein Institutes, Northwell Use Ultrasound to Treat Brain Tumors in Novel Clinical Trial | Researchers enrolled the first set of patients in the Alpheus Medical phase 1 clinical trial for people with recurrent brain tumors |
| 09.01.2023 | Imbria Enrolls First Patient in the Phase 2 IMPROVE-DiCE Clinical Trial Evaluating Ninerafaxstat in Patients with Heart Failure with Preserved Ejection Fraction | BOSTON, Jan. 09, 2023 (GLOBE NEWSWIRE) -- Imbria Pharmaceuticals, Inc., a clinical stage, cardiometabolic company developing novel therapies designed to enhance cellular energetics, today announced the enrollment of the first patient in Par... |
| 09.01.2023 | TRexBio Announces Collaboration and License Agreement with Lilly to Develop and Commercialize Novel Therapies for Immune-Mediated Diseases | Collaboration leverages TRexBio’s Deep Biology platform, which maps regulatory T cell (Treg) behavior in human tissue to identify and target immune-regulatory pathways for novel therapeutic development |
| 09.01.2023 | Exclusive: Eli Lilly boosts inflammatory disease pipeline, licenses three candidates from TRexBio | Eli Lilly is adding three new preclinical candidates to its immune and inflammatory medicines armory through TRexBio, a Bay Area biotech that specializes in T regulatory cells, or Tregs. |
| 05.01.2023 | QurAlis Announces First-in-Human Dose in Phase 1 Clinical Trial of QRL-101, a First-in-Class Kv7 Precision Therapy for ALS | QRL-101 aims to reduce hyperexcitability-induced motor neuron degeneration |
| 26.12.2022 | Why a lucky few may help the rest of us beat disease | A British biotech firm [Alchemab] believes patients who defy odds could hold the key in their blood, Tom Whipple writes |
| 20.12.2022 | Mestag Therapeutics appoints Prof. Ton Logtenberg as Chair | CAMBRIDGE, England, Dec. 20, 2022 /PRNewswire/ -- Mestag Therapeutics ("Mestag"), an immunotherapy company harnessing new insights into fibroblast-immune interactions in cancer and inflammatory disease, today announced the appoint... |
| 13.12.2022 | In its largest single-asset purchase ever, Takeda snaps up TYK2 drug [from SV portfolio company] for $4B upfront | Takeda is buying Nimbus’ late-stage TYK2 inhibitor, an oral drug for autoimmune diseases, for $4 billion in cash upfront. That sets Takeda up to compete with Bristol Myers Squibb, which got the first TYK2 inhibitor approval in September for... |
| 13.12.2022 | Dementia Discovery Fund invests in Amphista Therapeutics as it targets neurodegenerative diseases | Cambridge, UK – December 13, 2022 – Amphista Therapeutics, a leader in next generation targeted protein degradation (TPD) approaches, today announced a Series B extension investment by the Dementia Discovery Fund (DDF). The investment is in... |
| 13.12.2022 | Takeda to Acquire Nimbus Therapeutics’ Highly Selective, Allosteric TYK2 Inhibitor to Address Multiple Immune-Mediated Diseases | – Nimbus to receive $4 billion in upfront cash, and up to $2 billion in commercial milestone payments – |
| 08.12.2022 | QurAlis Receives Health Canada Clinical Trial Application Authorization for QRL-201, a First-in-Class STATHMIN-2 Precision Therapy for ALS | First ever study to evaluate a therapy that rescues STATHMIN-2 expression in ALS patients expected to initiate in Canada in early 2023 with other countries to follow |
| 06.12.2022 | Alison Burkland, co-founder of MCF portfolio company Nanopath, has been named one of Forbes' 30 under 30 | Alison Burklund is the cofounder and CTO of Nanopath. Nanopath creates diagnostics that test pelvic and gynecologic infections during a single visit, so treatment can begin right away. Recently, the company closed a Series A funding round o... |
